# Prognosis of locally advanced rectal cancer can be predicted more accurately using pre- and post-chemoradiotherapy neutrophil-lymphocyte ratios in patients who received preoperative chemoradiotherapy.

- **DOI:** [10.1371/journal.pone.0173955](https://doi.org/10.1371/journal.pone.0173955)
- **Rating:** Sound (3.1 out of 5)
- **Verdict:** A competent retrospective prognostic study that adds combined pre/post-CRT NLR stratification, limited mainly by unvalidated data-derived cut-offs.
- **Framework version:** v5.0
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-06-26
- **Evaluation page:** https://www.nabu.science/paper/10.1371%2Fjournal.pone.0173955

## Strengths

- **Clinically relevant prognostic-marker question** The study addresses heterogeneity in prognosis after preoperative CRT for locally advanced rectal cancer and asks whether pre- and post-treatment inflammatory markers can improve risk stratification. This is anchored in a treatment setting where the article states predictive markers are needed.
  - Dimension: contribution
  - Location: Introduction, paragraph 1
- **Defined treatment and measurement timing** The methods specify CRT, surgery, adjuvant chemotherapy, and NLR measurement timing, including post-CRT NLR from CBC at four weeks after CRT. This supports interpretability of the prognostic timing relative to outcomes.
  - Dimension: methodological rigour
  - Location: Materials and Methods, Preoperative CRT; Surgery; Adjuvant Chemotherapy; NLR
- **Clear survival-gradient presentation** The Results report a sequential decline in 3-year DFS and OS across NLR groups, with additional LRFS, DMFS, and failure-pattern reporting. The grouping scheme and outcome comparisons are presented in a way that makes the central association understandable.
  - Dimension: reporting
  - Location: Results, DFS, LRFS, DMFS, OS, and failure patterns
- **Relevant prior NLR literature engaged** The Discussion compares the study with earlier rectal-cancer NLR studies and explains why pre-CRT cut-off values varied across prior reports. This gives the incremental post-CRT and combined-marker claim a clear literature frame.
  - Dimension: positioning
  - Location: Discussion, paragraphs on Carruthers, Nagasaki, and Shen studies

## Limitations

- **Unvalidated outcome-derived NLR cut-offs** The cut-offs of 1.75 and 5.14 were selected using maximally selected log-rank testing with DFS in the same cohort used for prognostic evaluation. Without bootstrap, split-sample, or external validation, the apparent discrimination and exact thresholds are vulnerable to overfitting.
  - Dimension: methodological rigour
  - Location: Materials and Methods, Statistical Analyses; Results, NLR grouping and comparison between NLR groups
- **Small single-centre retrospective cohort** The analysis includes 110 patients from one hospital over 2006–2013, with a median follow-up of 31.1 months. This limits model stability, subgroup inference, and generalisability of the proposed grouping scheme.
  - Dimension: methodological rigour
  - Location: Materials and Methods, Patients; Results, DFS, LRFS, DMFS, OS, and failure patterns
- **Management implication exceeds evidence** The Discussion states that more aggressive adjuvant chemotherapy should be considered for group C, but the study is an observational prognostic analysis rather than a treatment-effect study. This limits the clinical-actionability of the finding.
  - Dimension: application pathway
  - Location: Discussion, paragraph on DMFS/systemic failure
- **Limited conduct transparency signals** The article declares institutional review board approval but provides no visible IRB identifier, conflict-of-interest statement, data availability statement, or code availability statement in the supplied text. These gaps affect inspectability rather than overturning the reported results.
  - Dimension: methodological rigour
  - Location: Materials and Methods, Patients; supplied full text overall

## Reliability checks

Caveats (4 of 4 checks).

- **Internal coherence:** Noted. The paper is broadly internally consistent in sample counts, endpoints, and main survival results. Internal coherence is nevertheless noted because the same dataset is used to derive and evaluate NLR cut-offs, the Discussion calls these cut-offs optimal, and one treatment-intensification implication exceeds the retrospective prognostic design.
- **Research conduct:** Noted. Ethics approval is declared for the retrospective chart review, but no IRB identifier or corroborating detail is visible in the supplied article. No explicit conflict-of-interest, data-availability, code-availability, preregistration, or reporting-standard declaration is present.
- **Reference integrity:** Clean. All 36 cited references resolved to real publications via PubMed, Crossref, or OpenAlex.
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
